Effects of Teriparatide Compared with Risedronate on Recovery After Pertrochanteric Hip Fracture: Results of a Randomized, Active-Controlled, Double-Blind Clinical Trial at 26 Weeks

What Was Tested

This randomized controlled trial paper looks at Teriparatide.

Osteoporosis drugs might affect fracture-healing.

See Instructions for Authors for a complete description of levels of evidence.

Who Took Part

The age groups tagged for this paper are older adults and people over 80, both men and women.

The main inclusion criteria were a bone mineral density T-score of ≤-2.0 and 25-OH-vitamin D of ≥9.2 ng/mL.

During the first 26 weeks, patients received study medication with oral or injectable placebo plus calcium and vitamin D in a double-blinded fashion.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.

Random assignment meant chance, not the researchers, decided who got Teriparatide and who got the comparison, which limits bias.

As a double-blind Teriparatide study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Teriparatide, giving a reference point.

Running at several centres spread the Teriparatide study over different clinics and patient groups.

Secondary (Timed Up-and-Go [TUG] test, hip pain, Short Form [SF]-36 health status, and safety) and exploratory (radiographic outcomes and ability to walk) 26-week end points are reported.

What Was Measured

See Instructions for Authors for a complete description of levels of evidence.

Topics PubMed links to this paper include Bone Density, Bone Density Conservation Agents, Fracture Healing, Hip Fractures, Risedronic Acid and Teriparatide.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Teriparatide.

The abstract goes on to report its results in about 10 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2016 (The Journal of bone and joint surgery. American volume), a journal based in United States.

More context: the Teriparatide compound page, all human trials.